

Nutritional issues in inflammatory bowel disease

Brian Behm MD MS
Associate Professor of Medicine
Division of Gastroenterology
University of Virginia
VASPEN 2015

Objectives

- Identify disease factors that impact the nutritional status of patients with inflammatory bowel disease (IBD)
- Review pathophysiology and potential treatment options for IBD
- Discuss the impact of diet, probiotics, prebiotics on IBD activity




Inflammatory bowel disease: overview

- Epidemiology
 - Prevalence: 1-1.5 million in U.S.
 - Peak incidence: 15-30 years
 - Annually: 6 million outpatient visits, 170K hospitalizations
 - > \$6 billion direct costs annually

The cause of IBD remains unknown There is no cure for IBD, only "remission"

IBD - Global Prevalence



Changes in IBD Incidence





Fig. 5 Changes in the incidence of Crohn's disease in recent decades in various geographical areas. Initial and most recent figures are given with occasional intermediate figures.



- Diffuse mucosal inflammation limited to colon
- Affects rectum
- May involve all or part of rest of colon



- Patchy transmural inflammation
- May affect any part of GI tract







CD

Anatomic Distribution

Freq. of involvement most least


Small bowel alone 33% -

lleocolic 45% -


Colon alone 20% -



CD - Clinical Patterns











IBD Genetics

- 163 IBD-associated loci
 - More than any other chronic disease
- Crohn's stronger genetic component than UC (twin studies- 50 v 19%)



The human microbiome




>1000 species in gut microbiome.

Stomach-nearly sterile in presence of gastric acid

Small intestine 10⁴ - 10⁷ microbes

Colon >10¹⁴ total microbes

10x number of cells in the body 150x number of genes





Host immune response- double-edged sword

Inflammatory response is required for pathogen defense, but causes tissue damage

Crohn's disease: Too little innate immunity

Ulcerative colitis: Too much innate immunity





Factors altering nutritional status in IBD

- Decreased intake/anorexia
- Nausea, vomiting, diarrhea
- Restrictive diets
- Medication side effects
- GI blood loss
- Protein loss from intestinal inflammation
- Malabsorption
- Surgical resections
- Increased vitamin and mineral needs
- Bacterial overgrowth




IBD flares

85% hospitalized IBD patients have protein-energy malnutrition



Goals of Therapy for IBD





Ulcerative Colitis

Induction

- 5-Aminosalicylates
- Corticosteroids
- Cyclosporine
- Anti-TNF
 - Infliximab
 - Adalimumab
 - Golimumab
 - Vedolizumab

Maintenace

- 5-Aminosalicylates
- Azathioprine/6MP
- Anti-TNF

• Infliximab

Adalir

Golim

Vedol





Crohn's disease

Induction

- 5-ASA
- Corticosteroids
- Biologics
 - Infliximab
 - Adalimumab
 - Certolizumab pegol
 - Natalizumab
 - Vedolizumab

Maintenance

- Azathioprine/6-MP
- Methotrexate
- Biologics
 - Infliximab
 - Adalimumab
 - Certolizumab pegol
 - Natalizumab
 - Vedolizumab



IBD diet

- General recommendation- follow a normal healthy diet as tolerated
- lactose intolerance 10-20% of IBD patients
- Enteral nutrition may induce remission in Crohn's
- Elemental, semi-elemental, polymeric formulas



Probiotics in IBD

- Crohn's disease- no evidence
- Ulcerative colitis possibly (E coli Nissle 1917, VSL#3 for maintenance of remission)



Diet modification

• Conflicting data on benefits of low carbohydrate diets, fiber, omega-3, antioxidants.



Total parenteral nutrition

- AGA position statement- no benefit in the routine treatment of IBD
- Increased risk